On Small-Cell Lung Cancer
Blackhall FH, Shepherd FA: Small cell lung cancer and targeted therapies. Curr Opin Oncol 19:103–108, 2007.
De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al: Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24:1057–1063, 2006.
Fried DB, Morris DE, Poole C, et al: Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837–4845, 2004.
Glisson BS: Recurrent small cell lung cancer: Update. Semin Oncol 30:72–78, 2003.
Komaki R, Paulus R, Ettinger DS, et al: A phase-II study of accelerated high-dose thoracic radiation therapy (AHTRT) with concurrent chemotherapy for limited small cell lung cancer: RTOG 0239. J Clin Oncol 27(15S):abstract 7527, 2009.
Lara PN Jr, Natale R, Crowley J, et al: Phase III trial of irinotecan(Drug information on irinotecan)/cisplatin compared with etoposide(Drug information on etoposide)/cisplatin in extensive-stage small-cell lung cancer: Clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27:2530–2535, 2009.
Le Péchoux C, Dunant A, Senan S, et al: Standard dose versus higher dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01: A randomised clinical trial. Lancet Oncol 10:467–474, 2009.
Movsas B, Moughan J, Komaki R, et al: Radiotherapy Patterns of Care Study in lung carcinoma. J Clin Oncol 21:4553–4559, 2003.
O'Brien ME, Ciuleanu TE, Tsekov H, et al: Phase III trial comparing supportive care alone with supportive care with oral topotecan(Drug information on topotecan) in patients with relapsed small-cell lung cancer. J Clin Oncol 24:5441–5447, 2006.
Slotman B, Faivre-Finn C, Kramer G, et al: Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 357:664–672, 2007.
Tashi T, Aldoss, IT, Gonsalves W, et al: Surgical resection in early limited-stage small-cell lung cancer: Time to rethink? A retrospective analysis of the VA central cancer registry. J Clin Oncol 29(S):abstract 7021, 2011.
Wolfson AH, Bae K, Komaki R, et al: Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: Impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys 81:77–84, 2011.
Flores RM, Pass HI, Seshan VE, et al: Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. J Thorac Cardiovasc Surg 135:620–626, 2008.
Ray M, Kindler HL: Malignant pleural mesothelioma: An update on biomarkers and treatment. Chest 136:888–896, 2009.
Tilleman TR, Richards WG, Zellos L, et al: Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin(Drug information on cisplatin) with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: A phase II prospective study. J Thorac Cardiovasc Surg 138:405–411, 2009.
Treasure T, Lang-Lazdunski L, Waller D, et al: Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763–772, 2011.
Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed(Drug information on pemetrexed) in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644, 2003.
Detterbeck FC, Huang H, eds: Definitions, policies, and procedures for assessing clinical outcomes for thymic malignancies as adopted by the International Thymic Malignancies Interest Group. J Thorac Oncol 6(Suppl 3), 2011.
Huang J, Rizk NP, Travis WD, et al: Feasibility of multimodality therapy including extended resections in stage IVA thymoma. J Thorac Cardiovasc Surg 134:1477–1483, 2007.
Kim ES, Putnam JB, Komaki R, et al: A phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: Final report. Lung Cancer 44:369–379, 2004.
Marulli G, Rea F, Melfi F, et al: Robot-aided thymectomy for early-stage thymoma: A multicenter European study. J Thorac Cardiovasc Surg 144:1125–1130, 2012.